COMMUNIQUÉS West-GlobeNewswire

BriaCell Therapeutics Announces Proposed Public Offering
11/12/2024
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that [...]
BrightSpring Health Services, Inc. Announced Refinancing of Term Loan B
11/12/2024
LOUISVILLE, Ky., Dec. 11, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex [...]
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
11/12/2024
Châtillon, France, December 11 th , 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements [...]
DBV confirme l’alignement avec la FDA (US) sur la procédure d'approbation accélérée du patch Viaskin® Peanut chez les enfants âgés de 1 à 3 ans
11/12/2024
Châtillon, France, le 11 décembre (22 :05 CEST) 2024 DBV confirme l’alignement avec la FDA (US) sur la procédure d'approbation accélérée du patch Viaskin® Peanut chez les enfants âgés de 1 à 3 ans DBV et la FDA se sont [...]
FemPulse Receives FDA IDE Approval for the Pivotal Clinical Trial of its Wearable Bioelectronic Device for Overactive Bladder in Women
11/12/2024
SAN FRANCISO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- FemPulse™ announced today Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin its EVANESCE II pivotal clinical trial [...]
SS Innovations Announces Completion of BDO Audit Process and Issues Update on Plans for NASDAQ Uplisting
11/12/2024
FORT LAUDERDALE, Fla., Dec. 11, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “ Company ” or “ SS Innovations ”) (OTC: SSII), developer of innovative surgical robotic technologies dedicated to making [...]
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025
11/12/2024
Currently enrolling randomized, double-blind, placebo-controlled, dose-finding, Phase 2 clinical trial to evaluate the safety and efficacy of KDS2010 in patients with Alzheimer’s disease with mild cognitive impairment [...]
CancerVax Targets Hard to Treat Pancreatic Cancer
11/12/2024
With limited options available to treat Pancreatic Ductal Adenocarcinoma (PDAC), the Company’s Universal Cancer Treatment Platform may provide hope for patients and doctors Lehi, UT, Dec. 11, 2024 (GLOBE NEWSWIRE) -- [...]
Dr. Steinbrech Unveils the Top 10 Most Requested Faces in Male Plastic Surgery for 2024
11/12/2024
World-renowned plastic surgeon, Dr. Steinbrech, today released his highly anticipated annual list of the most requested celebrity faces in male plastic surgery. This year's rankings offer a fascinating glimpse into the [...]
Bond by Solana Labs Partners with Baxus and Iridia to Debut Onchain Molecular Authentication Tech
11/12/2024
SAN FRANCISCO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Bond by Solana Labs , a web3 platform designed to elevate customer engagement for brands, is partnering with leading spirits marketplace Baxus and molecular identity [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 novembre 2024
11/12/2024
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 novembre 2024 En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF, [...]
AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET
11/12/2024
PRESS RELEASE AB SCIENCE WILL HOST A LIVE WEBCAST ON MONDAY DECEMBER 16, 2024 FROM 5.30PM TO 6.30PM CET Paris, 11 December, 2024, 6pm CET AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on Monday [...]
AB Science tiendra une conférence virtuelle le lundi 16 décembre 2024, de 17h30 à 18h30
11/12/2024
COMMUNIQUE DE PRESSE AB SCIENCE TIENDRA UNE CONFERENCE VIRTUELLE LE LUNDI 16 DECEMBRE 2024, DE 17H30 A 18H30 Paris, 11 décembre 2024, 18h AB Science SA (Euronext – FR0010557264 – AB) tiendra une conférence virtuelle le [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of November 30, 2024
11/12/2024
Disclosure of Share Capital and Voting Rights Outstanding as of November 30, 2024 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 30 novembre 2024
11/12/2024
Nombre total de droits de vote et d’actions composant le capital social au 30 novembre 2024 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®
11/12/2024
OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® ARTEMIA: Clinical trial protocol approved globally. Most countries and sites activated, with full activation [...]
OSE Immunotherapeutics annonce des avancées cliniques positives de Tedopi®, son vaccin thérapeutique contre le cancer en développement avancé
11/12/2024
OSE Immunotherapeutics annonce des avancées cliniques positives de Tedopi®, son vaccin thérapeutique contre le cancer en développement avancé ARTEMIA : Protocole de l’essai clinique approuvé au niveau mondial. Une [...]
TECVAYLI®▼ (téclistamab) révèle son potentiel en tant que traitement combiné de première ligne destiné aux patients atteints d’un myélome multiple nouvellement diagnostiqué
11/12/2024
100 pour cent des patients chez qui la maladie résiduelle minimale (MRM) était évaluable ont atteint une MRM négative dans le cadre de l’étude MajesTEC-5 évaluant le produit en traitement d’induction, et dans le cadre [...]
RapidPulse Receives FDA Approval to Begin IDE Study in Ischemic Stroke Using Innovative Cyclic Aspiration System – Recently Completed Clinical Trial Shows Significantly Higher First Pass and Frontline Success Rates
11/12/2024
MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) -- RapidPulse, Inc., a Delaware corporation headquartered in Miami, Florida focused on improving the treatment success rate for acute ischemic stroke (AIS) announced that the United [...]

Pages